Aninda Mazumdar

Mr. Aninda Mazumdar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
PJPavlina Jelinkova
Pavlina Jelinkova
AMAninda Mazumdar
Aninda Mazumdar
Vishma Pratap SurVishma Pratap Sur
Vishma Pratap Sur
SKSilvia Kociova
Silvia Kociova
KDKristyna Dolezelikova
Kristyna Dolezelikova
Vojtech AdamVojtech Adam
Vojtech Adam

1 November 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
SBSukanya Bhowmick
Sukanya Bhowmick
AMAninda Mazumdar
Aninda Mazumdar
Amitava MoulickAmitava Moulick
Amitava Moulick
Vojtech AdamVojtech Adam
Vojtech Adam

15 September 2025 in Nature Methods
Verified
Journal Article
Open access
PDF file
CBCorinna Brungs
Corinna Brungs
RSRobin Schmid
Robin Schmid
SHSteffen Heuckeroth
Steffen Heuckeroth
AMAninda Mazumdar
Aninda Mazumdar
MDMatúš Drexler
Matúš Drexler
TPTomáš Pluskal
Tomáš Pluskal
Untargeted high-resolution mass spectrometry is a key tool in clinical metabolomics, natural product discovery and exposomics, with compound identification remaining the major bottleneck. Currently, the standard workflow applies spectral library matching against tandem mass spectrometry (MS 2 ) fragmentation data. Multi-stage fragmentation (MS n ) yields more profound insights into substructures, enabling validation of fragmentation pathways; however, the community lacks open MS n reference data of diverse natural products and other chemicals. Here we describe MS n Lib, a machine learning-ready open resource of >2 million spectra in MS n trees of 30,008 unique small molecules, built with a high-throughput data acquisition and processing pipeline in the open-source software mzmine.

1 October 2018 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
PJPavlína Jelínková
Pavlína Jelínková
ZSZbynek Splichal
Zbynek Splichal
AJAna Maria Jimenez Jimenez
Ana Maria Jimenez Jimenez
YHYazan Haddad
Yazan Haddad
AMAninda Mazumdar
Aninda Mazumdar
Vojtech AdamVojtech Adam
Vojtech Adam
Background: Increase in vancomycin (Van)-resistant bacterial strains including vancomycin-resistant Staphylococcus aureus (VRSA) and lack of new effective antibiotics have become a formidable health problem. Materials and methods: We designed a new conjugate composed of Van and a peptide Hecate (Hec; Van/Hec), and its potential antimicrobial activity was evaluated. Results: Results from disk diffusion test, time-kill assay, determination of minimum inhibitory concentration (MIC), microscopy, and comet assay showed strong antimicrobial effects of Van/Hec against wild-type, methicillin-resistant Staphylococcus aureus (MRSA) and VRSA. Microscopy revealed that the exposure to Van/Hec results in disruption of bacterial cell integrity in all tested strains, which was not observed in case of Van or Hec alone. Conclusion: Overall, we showed that the preparation of conjugates from antibiotics and biologically active peptides could help us to overcome the limitation of the use of antibiotic in the treatment of infections caused by multidrug-resistant bacteria.

14 February 2020 in Nanomaterials
Verified
Journal Article
Open access
PDF file
AMAninda Mazumdar
Aninda Mazumdar
YHYazan Haddad
Yazan Haddad
VMVedran Milosavljevic
Vedran Milosavljevic
HMHana Michalkova
Hana Michalkova
RGRoman Guran
Roman Guran
Amitava MoulickAmitava Moulick
Amitava Moulick
Antibiotic-resistant bacterial infections have become global issues for public health, which increases the utter need to develop alternatives to antibiotics. Here, the HSER (Homo sapiens retinoic acid receptor) peptide was designed from retinoic acid receptor responder protein 2 of Homo sapiens, and was conjugated with synthesized CQDs (carbon quantum dots) for enhanced antibacterial activity in combination, as individually they are not highly effective. The HSER–CQDs were characterized using spectrophotometer, HPLC coupled with electrospray-ionization quadrupole time-of-flight mass spectrometer (ESI–qTOF) mass spectrometer, zeta potential, zeta size, and FTIR. Thereafter, the antibacterial activity against Vancomycin-Resistant Staphylococcus aureus (VRSA) and Escherichia coli (carbapenem resistant) was studied using growth curve analysis, further supported by microscopic images showing the presence of cell debris and dead bacterial cells. The antibacterial mechanism of HSER–CQDs was observed to be via cell wall disruption and also interaction with gDNA (genomic DNA). Finally, toxicity test against normal human epithelial cells showed no toxicity, confirmed by microscopic analysis. Thus, the HSER–CQDs conjugate, having high stability and low toxicity with prominent antibacterial activity, can be used as a potential antibacterial agent.

Verified
Journal Article
Open access
PDF file
Vishma Pratap SurVishma Pratap Sur
Vishma Pratap Sur
AMAninda Mazumdar
Aninda Mazumdar
Pavel KopelPavel Kopel
Pavel Kopel
Soumajit MukherjeeSoumajit Mukherjee
Soumajit Mukherjee
PVPetr Vitek
Petr Vitek
Amitava MoulickAmitava Moulick
Amitava Moulick
The current epidemic of antibiotic-resistant infections urges to develop alternatives to less-effective antibiotics. To assess anti-bacterial potential, a novel coordinate compound (RU-S4) was synthesized using ruthenium-Schiff base-benzimidazole ligand, where ruthenium chloride was used as the central atom. RU-S4 was characterized by scanning electron microscope (SEM), energy-dispersive X-ray spectroscopy (EDS), and Raman spectroscopy. Antibacterial effect of RU-S4 was studied against Staphylococcus aureus (NCTC 8511), vancomycin-resistant Staphylococcus aureus (VRSA) (CCM 1767), methicillin-resistant Staphylococcus aureus (MRSA) (ST239: SCCmecIIIA), and hospital isolate Staphylococcus epidermidis. The antibacterial activity of RU-S4 was checked by growth curve analysis and the outcome was supported by optical microscopy imaging and fluorescence LIVE/DEAD cell imaging. In vivo (balb/c mice) infection model prepared with VRSA (CCM 1767) and treated with RU-S4. In our experimental conditions, all infected mice were cured. The interaction of coordination compound with bacterial cells were further confirmed by cryo-scanning electron microscope (Cryo-SEM). RU-S4 was completely non-toxic against mammalian cells and in mice and subsequently treated with synthesized RU-S4.